GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Recombinant expression of Yersinia ruckeri outer membrane proteins in Escherichia coli extracellular vesicles
    Elsevier BV ; 2024
    In:  Protein Expression and Purification Vol. 215 ( 2024-03), p. 106409-
    Details
    In: Protein Expression and Purification, Elsevier BV, Vol. 215 ( 2024-03), p. 106409-
    Type of Medium: Online Resource
    ISSN: 1046-5928
    URL: Article
    DOI: 10.1016/j.pep.2023.106409
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2024
    detail.hit.zdb_id: 1471688-4
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Perceived Benefits and Barriers Regarding CSII Treatment: Development and Psychometric Evaluation of the Insulin Pump Attitudes Questionnaire (IPA-Questionnaire)
    Georg Thieme Verlag KG ; 2021
    In:  Experimental and Clinical Endocrinology & Diabetes Vol. 129, No. 08 ( 2021-08), p. 566-573
    Details
    In: Experimental and Clinical Endocrinology & Diabetes, Georg Thieme Verlag KG, Vol. 129, No. 08 ( 2021-08), p. 566-573
    Abstract: Background Continuous subcutaneous insulin infusion is the most advanced and demanding form of insulin therapy. Various positive and negative expectations, attitudes and experiences can occur, influencing adherence to and efficacy of continuous subcutaneous insulin infusion therapy. A new questionnaire was developed to systematically assess perceived benefits, perceived barriers and handling of continuous subcutaneous insulin infusion therapy. Methods The Insulin Pump Attitude Questionnaire was tested in two samples (n=265/452) comprising pump users and non-pump users. Reliability was assessed using Cronbach’s Alpha estimation. Exploratory and confirmatory factor analyses were conducted to establish the factorial structure. Correlations with other questionnaires as well as group differences between pump users and non-pump users were used to assess validity. Results Exploratory factor analysis revealed 26 items comprising six subscales: “Glycaemic Control”, “Flexibility”, “Impaired Body Image”, “Technology Dependency”, “Ease Of Use” and “Functionality”. Confirmatory factor analysis confirmed this factor structure. The IPA sum score correlated significantly with diabetes distress (r=−0.30), self-efficacy (r=0.22), diabetes empowerment (r=0.36), psychological well-being (r=0.16) and treatment dissatisfaction (r=−0.24), supporting criterion validity with small to medium effect sizes. Furthermore, the IPA was able to differentiate between pump users and non-pump users with higher scores for pump users regarding “Glycaemic Control”, “Flexibility”, “Ease of use” and “Functionality” and lower scores for pump users regarding “Impaired Body Image” and “Technology Dependency”. Conclusions The Insulin Pump Attitude Questionnaire is a reliable and valid new instrument to assess attitudes towards continuous subcutaneous insulin infusion. With six scales, the Insulin Pump Attitude Questionnaire provides a comprehensive analysis of possible benefits, barriers, and handling problems of continuous subcutaneous insulin infusion therapy. In clinical practice, the Insulin Pump Attitude Questionnaire might be used to address the different attitudes in pump users but also in people considering continuous subcutaneous insulin infusion therapy.
    Type of Medium: Online Resource
    ISSN: 0947-7349 , 1439-3646
    URL: Article
    DOI: 10.1055/a-0899-4980
    RVK:
    XA 42403
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Spiritual Care in the Intensive Care Unit : Experiences of Dutch Intensive Care Unit Patients and Relatives
    Ovid Technologies (Wolters Kluwer Health) ; 2023
    In:  Dimensions of Critical Care Nursing Vol. 42, No. 2 ( 2023-3), p. 83-94
    Details
    In: Dimensions of Critical Care Nursing, Ovid Technologies (Wolters Kluwer Health), Vol. 42, No. 2 ( 2023-3), p. 83-94
    Type of Medium: Online Resource
    ISSN: 1538-8646 , 0730-4625
    URL: Article
    DOI: 10.1097/DCC.0000000000000570
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2023
    detail.hit.zdb_id: 2053433-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    795-P: Significance and Future Trends of AID Systems from the Perspective of Physicians
    American Diabetes Association ; 2022
    In:  Diabetes Vol. 71, No. Supplement_1 ( 2022-06-01)
    Details
    In: Diabetes, American Diabetes Association, Vol. 71, No. Supplement_1 ( 2022-06-01)
    Abstract: Aims: How do physicians assess AID-Systems in terms of their current and future importance for diabetes care? Methods: In 2021 3diabetologists in Germany (48% female, average age 53.7 years) were asked via online surveys about their current and future assessment of AID-Systems.The results were compared with the 20survey, in which 337 diabetologists (43% female, mean age 53.2 years) participated. Results: Currently, 58.6% (2020: 51.4%) of diabetologists consider AID-Systems to be important for diabetes care, in 5 years 89.3% (2020: 86.4%) . Diabetologists estimate that in approx. 9 years one in two PwD TD1 in Germany will be a user of an AID-System, and in approx. 17 years 90% will use an AID-System. Currently, they estimate that 57.6% of all PwD-TD1 are suitable for an AID-System. Diabetologists see the clearest impact of AID-Systems in an increased need for diabetes selfmangement education (78.9%) , but also in PwD becoming much more autonomous and empowered (62.8%) . Regarding possible negative effects of AID-Systems, diabetologists see only few risks: 20% fear that PWD will have less contact with the diabetes team, 16.9% are concerned that PWD will not be able to cope with the technological change. Only 7.9% fear that PWD will become riskier with AID-Systems, only 1.7% have fears that the diabetes team will become superfluous. Conclusions: Overall, diabetologists assess AID-Systems as a important innovation for diabetes care and that this will soon become the standard therapy for T1D. The effort for Diabetes self-management education and support is estimated to be relatively high, possible disadvantages relatively low. Disclosure L.Heinemann: Board Member; Lifecare, Inc., Consultant; Becton, Dickinson and Company, Roche Diabetes Care, Stock/Shareholder; Profil Institut für Stoffwechselforschung GmbH, Science Consulting in Diabetes GmbH. N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi. D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. T.Roos: None. B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care.
    Type of Medium: Online Resource
    ISSN: 0012-1797
    URL: Article
    DOI: 10.2337/db22-795-P
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2022
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    666-P: How Satisfied Are People with Type 2 Diabetes with a Basal Insulin Titration App? Findings from the Intervention Group of a Randomized Controlled Trial
    American Diabetes Association ; 2023
    In:  Diabetes Vol. 72, No. Supplement_1 ( 2023-06-20)
    Details
    In: Diabetes, American Diabetes Association, Vol. 72, No. Supplement_1 ( 2023-06-20)
    Abstract: A randomized controlled trial (RCT) was conducted to evaluate the efficacy of the myDoseCoach app, an insulin titration app for basal insulin for people with type 2 diabetes. We asked app users in this study to evaluate the quality of the app via a modified version of the Mobile App Rating Scale (MARS). A total of 120 participants (median age: 60.0 yrs; A1C 8.1%; BMI 31.8 kg/m², diabetes duration 10.0 yrs., 39.0% female) of the intervention arm completed the MARS. Reliability of the 11 item version was high with Cronbach’s α = 0.915. Mean MARS rating was 4.4 (range 1-5), indicating a rather high quality rating. Less than 10% indicated a low quality of the app (rating & lt;3); 10% were indifferent and more that 70% rated the quality of the app as “4” or higher. Figure 1 shows the ratings of the 11 single items. Bivariate correlations showed that neither older age (r=-0.064; p=0.322) nor gender (r=0.102; p=0.180) were significantly associated with the quality rating. The results indicate that the vast majority of the app users evaluated the quality of the App positively with regard to its engagement, functionality, aesthetics, and information quality. Disclosure D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. T.Roos: None. K.Finke-groene: None. B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care. Funding Sanofi
    Type of Medium: Online Resource
    ISSN: 0012-1797
    URL: Article
    DOI: 10.2337/db23-666-P
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2023
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Assessing attitudes towards insulin pump therapy in adults with type 1 diabetes: Italian validation of the Insulin Pump Attitudes Questionnaire (IT-IPA questionnaire)
    Springer Science and Business Media LLC ; 2023
    In:  Acta Diabetologica Vol. 60, No. 5 ( 2023-02-20), p. 687-695
    Details
    In: Acta Diabetologica, Springer Science and Business Media LLC, Vol. 60, No. 5 ( 2023-02-20), p. 687-695
    Abstract: The aim of the study was to adapt the German version of the insulin pump therapy (IPA) questionnaire to Italian (IT-IPA) and to evaluate its psychometric properties in adults with type 1 diabetes. Methods We conducted a cross-sectional study, data were collected through an online survey. In addition to IT-IPA, questionnaires evaluating depression, anxiety, diabetes distress, self-efficacy, and treatment satisfaction were administered. The six factors identified in the IPA German version were assessed using confirmatory factor analysis; psychometric testing included construct validity and internal consistency. Results The online survey was compiled by 182 individuals with type 1 diabetes: 45.6% continuous subcutaneous insulin infusion (CSII) users and 54.4% multiple daily insulin injection users. The six-factor model had a very good fit in our sample. The internal consistency was acceptable (Cronbach’s α = 0.75; 95% IC [0.65–0.81]). Diabetes treatment satisfaction was positively correlated with a positive attitude towards CSII therapy (Spearman’s rho = 0.31; p   〈  0.01), less Technology Dependency, higher Ease of Use, and less Impaired Body Image. Furthermore, less Technology Dependency was associated with lower diabetes distress and depressive symptoms. Conclusions The IT-IPA is a valid and reliable questionnaire evaluating attitudes towards insulin pump therapy. The questionnaire can be used for clinical practice during consultations for shared decision-making to CSII therapy.
    Type of Medium: Online Resource
    ISSN: 1432-5233
    URL: Article
    DOI: 10.1007/s00592-023-02046-7
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 1468518-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Everolimus after failure of one prior VEGF ‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC ‐2 trial
    Wiley ; 2021
    In:  International Journal of Cancer Vol. 148, No. 7 ( 2021-04), p. 1685-1694
    Details
    In: International Journal of Cancer, Wiley, Vol. 148, No. 7 ( 2021-04), p. 1685-1694
    Abstract: What's new? While different novel treatment options have been approved for the vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) refractory setting in metastatic renal cell carcinoma (mRCC), choosing the optimal second‐line therapy regimen remains a biologic and therapeutic challenge. The MARC‐2 phase IV trial aimed to investigate clinical outcomes in mRCC patients treated with everolimus after failure of one VEGFR‐TKI therapy and to identify subgroups benefiting most. According to the data, everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy, with the greatest benefit seen in patients ≥65 years or with BMI 〉 25 kg/m 2 .
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    URL: Article
    DOI: 10.1002/ijc.v148.7
    DOI: 10.1002/ijc.33349
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    664-P: Efficacy of a Digital Diabetes Logbook for Reducing Treatment Burden—Results of a Randomized Controlled Trial
    American Diabetes Association ; 2023
    In:  Diabetes Vol. 72, No. Supplement_1 ( 2023-06-20)
    Details
    In: Diabetes, American Diabetes Association, Vol. 72, No. Supplement_1 ( 2023-06-20)
    Abstract: The digital diabetes logbook mySugr is designed to help people with diabetes manage their diabetes and to reduce burden of diabetes management. To test the efficacy of the app, a randomized controlled trial (RCT) was conducted. The RCT was designed as a multi-center, open-label, parallel study with a 3-month follow-up in Germany. Participants were randomized to either using the mySugr app or to the treatment-as-usual control group in a 2:1 ratio. Primary outcome was change in diabetes distress using the Problem Areas in Diabetes (PAID) questionnaire. Based on the power analysis, the recruitment goal was 396 participants, anticipating 15% drop-out it was planned to recruit 466 participants. Robust regression was used to analyze the data with follow-up scores as dependent variable, group as independent variable and controlled for respective baseline scores. Primary analysis was based on the intention-to-treat population with jump-to-reference approach for multiple imputation of missing data. A total of 424 people with diabetes were randomized, 282 to the intervention and 142 to the control group (12.5% type 1 diabetes, 68.2% type 2 diabetes, 18.9% gestational diabetes, age: 51.7±15.2 years, 50% female, diabetes duration: 9.5±10.8 years, A1c: 7.1±1.5%, PAID: 21.6±17.4); 397 completed the 3-month follow-up. Intention-to-treat analysis revealed a significant between-group difference in the primary outcome (p = 0.0182). PAID scores at follow-up in the mySugr group were significantly lower than in the control group (Δ -2.20, 95% CI: -4.02 to -0.38). This was corroborated by the per-protocol analysis (Δ -2.43, 95% CI: -4.49 to -0.37, p = 0.0211). Recruitment was successful and could be stopped earlier due to the very low drop-out rate (6.4%). Use of mySugr led to a significant improvement in diabetes distress after 3 months compared to the treatment-as-usual control group. Thus, the efficacy of mySugr regarding the reduction of diabetes distress could be demonstrated in the RCT. Disclosure D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. S.Silbermann: Employee; Roche Diabetes Care. J.Kober: Employee; mySugr. K.Finke-groene: None. T.Roos: None. I.Vesper: None. V.L.Schaefer: Employee; Roche Diabetes Care. B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care. Funding Roche Diabetes Care GmbH (DC000097)
    Type of Medium: Online Resource
    ISSN: 0012-1797
    URL: Article
    DOI: 10.2337/db23-664-P
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2023
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Operation and performance of the ATLAS semiconductor tracker in LHC Run 2
    IOP Publishing ; 2022
    In:  Journal of Instrumentation Vol. 17, No. 01 ( 2022-01-01), p. P01013-
    Details
    In: Journal of Instrumentation, IOP Publishing, Vol. 17, No. 01 ( 2022-01-01), p. P01013-
    Abstract: The semiconductor tracker (SCT) is one of the tracking systems for charged particles in the ATLAS detector. It consists of 4088 silicon strip sensor modules. During Run 2 (2015–2018) the Large Hadron Collider delivered an integrated luminosity of 156 fb -1 to the ATLAS experiment at a centre-of-mass proton-proton collision energy of 13 TeV. The instantaneous luminosity and pile-up conditions were far in excess of those assumed in the original design of the SCT detector. Due to improvements to the data acquisition system, the SCT operated stably throughout Run 2. It was available for 99.9% of the integrated luminosity and achieved a data-quality efficiency of 99.85%. Detailed studies have been made of the leakage current in SCT modules and the evolution of the full depletion voltage, which are used to study the impact of radiation damage to the modules.
    Type of Medium: Online Resource
    ISSN: 1748-0221
    URL: Article
    DOI: 10.1088/1748-0221/17/01/P01013
    Language: Unknown
    Publisher: IOP Publishing
    Publication Date: 2022
    detail.hit.zdb_id: 2235672-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Effects of hatching system on chick quality, welfare and health of young breeder flock offspring
    Elsevier BV ; 2023
    In:  Poultry Science Vol. 102, No. 3 ( 2023-03), p. 102448-
    Details
    In: Poultry Science, Elsevier BV, Vol. 102, No. 3 ( 2023-03), p. 102448-
    Type of Medium: Online Resource
    ISSN: 0032-5791
    URL: Article
    DOI: 10.1016/j.psj.2022.102448
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 2016331-9
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...